Mikhail Dvorkin
About
Mikhail Dvorkin is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Cancer Research.
According to data from OpenAlex, Mikhail Dvorkin has authored 43 papers receiving a total of 924 indexed citations (citations by other indexed papers that have themselves been cited), including 41 papers in Oncology, 18 papers in Pulmonary and Respiratory Medicine and 11 papers in Cancer Research. Recurrent topics in Mikhail Dvorkin's work include Lung Cancer Research Studies (13 papers), Lung Cancer Treatments and Mutations (10 papers) and Biosimilars and Bioanalytical Methods (9 papers). Mikhail Dvorkin is often cited by papers focused on Lung Cancer Research Studies (13 papers), Lung Cancer Treatments and Mutations (10 papers) and Biosimilars and Bioanalytical Methods (9 papers). Mikhail Dvorkin collaborates with scholars based in United States, Russia and Italy. Mikhail Dvorkin's co-authors include Igor Bondarenko, Yaroslav Shparyk, Ekaterina Trishkina, Alexey Manikhas, Matthew J. Ellis, Shinzaburo Noguchi, Servando Cardona‐Huerta, Lynda Grinsted, Kwok‐Leung Cheung and Lawrence Panasci and has published in prestigious journals such as The Lancet, Journal of Clinical Oncology and SHILAP Revista de lepidopterología.
In The Last Decade
Mikhail Dvorkin
42 papers receiving 906 citations
Hit Papers
Peers
Mikhail Dvorkin
Yien Ning Sophia Wong United Kingdom
Hidenobu Ishii Japan
Sabrina Rossi Italy
Zishuo I. Hu United States
Christopher Gresty United Kingdom
Marie Alt France
Charles Schneider United States
Melissa A. Reimers United States
David Vicente Spain
W. Li China
Citations per year, relative to Mikhail Dvorkin Mikhail Dvorkin (= 1×)
peers
Yien Ning Sophia Wong
Countries citing papers authored by Mikhail Dvorkin
Since
Specialization
Citations
This map shows the geographic impact of Mikhail Dvorkin's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Mikhail Dvorkin with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Mikhail Dvorkin more than expected).
Fields of papers citing papers by Mikhail Dvorkin
Since
Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences
This network shows the impact of papers produced by Mikhail Dvorkin. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Mikhail Dvorkin. The network helps show where Mikhail Dvorkin may publish in the future.
Co-authorship network of co-authors of Mikhail Dvorkin
This figure shows the co-authorship network connecting the top 25 collaborators of Mikhail Dvorkin. A scholar is included among the top collaborators of Mikhail Dvorkin based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Mikhail Dvorkin. Mikhail Dvorkin is excluded from the visualization to improve readability, since they are connected to all nodes in the network.
All Works
1.
Makharadze, Tamta, Ruben G.W. Quek, Tamar Melkadze, et al.. (2023). Quality of life with cemiplimab plus chemotherapy for first‐line treatment of advanced non–small cell lung cancer: Patient‐reported outcomes from phase 3 EMPOWER‐Lung 3. Cancer. 129(14). 2256–2265.
2.
Ciardiello, Fortunato, Yung‐Jue Bang, Andrés Cervantes, et al.. (2023). Efficacy and safety of maintenance therapy with pamiparib versus placebo for advanced gastric cancer responding to first‐line platinum‐based chemotherapy: Phase 2 study results. Cancer Medicine. 12(12). 13145–13154.
3.
Reddy, Pramod, et al.. (2023). Comparison of Efficacy and Safety of a Bevacizumab Biosimilar, in Combination with Chemotherapies, in Nonresectable Metastatic Colorectal Cancer and in Advanced Nonsquamous Non–Small Cell Lung Cancer: A Randomized, Double-Blind, Phase III Study. SHILAP Revista de lepidopterología. 13(1). 66–76.
4.
Султанбаев, А. В., et al.. (2023). Pharmacotherapy regimens for patients with hormone-receptor positive (HR+), human epidermal growth factor 2 negative (HER2–) metastatic breast cancer in routine clinical practice (results of non-interventional retrospective study). Medical alphabet. 7–14.
5.
Özgüroğlu, Mustafa, Saadettin Kılıçkap, Igor Bondarenko, et al.. (2022). LBA54 Three years survival outcome and continued cemiplimab (CEMI) beyond progression with the addition of chemotherapy (chemo) for patients (pts) with advanced non-small cell lung cancer (NSCLC): The EMPOWER-Lung 1 trial. Annals of Oncology. 33. S1421–S1421.
6.
Zhou, Chuanlong, Dongmei Huang, Yong Fan, et al.. (2022). 1031P Tislelizumab (TIS) versus docetaxel (TAX) as second- or third-line therapy in previously treated patients (pts) with locally advanced non-small cell lung cancer (NSCLC): Asian versus non-Asian subgroup analysis of the RATIONALE-303 study. Annals of Oncology. 33. S1026–S1027.
7.
Cheng, Ying, Liang Han, Lin Wu, et al.. (2022). Serplulimab, a novel anti-PD-1 antibody, plus chemotherapy versus chemotherapy alone as first-line treatment for extensive-stage small-cell lung cancer: An international randomized phase 3 study.. Journal of Clinical Oncology. 40(16_suppl). 8505–8505.
8.
Makharadze, Tamta, Ruben G.W. Quek, Tamar Melkadze, et al.. (2021). 93P Patient-reported outcomes (PROs) with cemiplimab or placebo plus platinum-doublet chemotherapy (chemo) for first-line (1L) treatment of advanced non-small cell lung cancer (aNSCLC): EMPOWER-Lung 3 trial. Annals of Oncology. 32. S1414–S1414.
9.
Mansoor, Wasat, Hendrik‐Tobias Arkenau, María Alsina, et al.. (2021). Trifluridine/tipiracil in patients with metastatic gastroesophageal junction cancer: a subgroup analysis from the phase 3 TAGS study. Gastric Cancer. 24(4). 970–977.
10.
Syrigos, Konstantinos, Igor Bondarenko, Mikhail Dvorkin, et al.. (2021). Efficacy and Safety of Bevacizumab Biosimilar FKB238 Versus Originator Bevacizumab: Results from AVANA, a Phase III Trial in Patients with Non-Squamous Non-Small-Cell Lung Cancer (non-sq-NSCLC). BioDrugs. 35(4). 417–428.
11.
Cohen, Ezra E.W., Robert L. Ferris, Amanda Psyrri, et al.. (2020). 910O Primary results of the phase III JAVELIN head & neck 100 trial: Avelumab plus chemoradiotherapy (CRT) followed by avelumab maintenance vs CRT in patients with locally advanced squamous cell carcinoma of the head and neck (LA SCCHN). Annals of Oncology. 31. S658–S658.
12.
Moehler, Markus, Mikhail Dvorkin, Mustafa Özgüroğlu, et al.. (2020). Results of the JAVELIN Gastric 100 phase 3 trial: avelumab maintenance following first-line (1L) chemotherapy (CTx) vs continuation of CTx for HER2− advanced gastric or gastroesophageal junction cancer (GC/GEJC).. Journal of Clinical Oncology. 38(4_suppl). 278–278.
13.
Su, Meng, Erika Hitre, Li‐Yuan Bai, et al.. (2019). EndoTAG-1 plus gemcitabine versus gemcitabine alone in patients with measurable locally advanced and/or metastatic adenocarcinoma of the pancreas failed on FOLFIRINOX treatment. Annals of Oncology. 30. iv23–iv23.
14.
Arkenau, Hendrik‐Tobias, Josep Tabernero, Kohei Shitara, et al.. (2018). TAGS: A phase III, randomised, double-blind study of trifluridine/tipiracil (TAS-102) versus placebo in patients with refractory metastatic gastric cancer. Annals of Oncology. 29. viii718–viii718.
15.
Pivot, Xavier, Igor Bondarenko, Zbigniew Nowecki, et al.. (2018). A phase III study comparing SB3 (a proposed trastuzumab biosimilar) and trastuzumab reference product in HER2-positive early breast cancer treated with neoadjuvant-adjuvant treatment: Final safety, immunogenicity and survival results. European Journal of Cancer. 93. 19–27.
16.
Pivot, Xavier, Igor Bondarenko, Zbigniew Nowecki, et al.. (2017). One-year safety, immunogenicity, and survival results from a phase III study comparing SB3 (a proposed trastuzumab biosimilar) and originator trastuzumab in HER2-positive early breast cancer treated with neoadjuvant-adjuvant treatment. Annals of Oncology. 28. v45–v45.
17.
Tabernero, Josep, Fortunato Ciardiello, Clara Montagut, et al.. (2017). Efficacy and safety of Sym004 in refractory metastatic colorectal cancer with acquired resistance to anti-EGFR therapy: Results of a randomized phase II study (RP2S). Annals of Oncology. 28. v160–v160.
18.
Pivot, Xavier, Igor Bondarenko, Mikhail Dvorkin, et al.. (2017). A randomized, double-blind, phase III study comparing SB3 (trastuzumab biosimilar) with originator trastuzumab in patients treated by neoadjuvant therapy for HER2-positive early breast cancer.. Journal of Clinical Oncology. 35(15_suppl). 509–509.
19.
Ellis, Matthew J., Igor Bondarenko, Ekaterina Trishkina, et al.. (2016). FALCON: A phase III randomised trial of fulvestrant 500 mg vs. anastrozole for hormone receptor-positive advanced breast cancer. Annals of Oncology. 27. vi554–vi554.
20.
Robertson, J.F.R., Igor Bondarenko, Ekaterina Trishkina, et al.. (2016). Fulvestrant 500 mg versus anastrozole 1 mg for hormone receptor-positive advanced breast cancer (FALCON): an international, randomised, double-blind, phase 3 trial. The Lancet. 388(10063). 2997–3005.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.
Explore authors with similar magnitude of impact
Breakdown of academic impact, for papers by Yien Ning Sophia Wong Breakdown of academic impact, for papers by Hidenobu Ishii Breakdown of academic impact, for papers by Sabrina Rossi Breakdown of academic impact, for papers by Zishuo I. Hu Breakdown of academic impact, for papers by Christopher Gresty Breakdown of academic impact, for papers by Marie Alt Breakdown of academic impact, for papers by Charles Schneider Breakdown of academic impact, for papers by Melissa A. Reimers Breakdown of academic impact, for papers by David Vicente Breakdown of academic impact, for papers by W. Li